Science

Yüksel Ürün: New Player in ARPI-Resistant Prostate Cancer

Yüksel Ürün/X

Jun 30, 2025, 14:40

Yüksel Ürün: New Player in ARPI-Resistant Prostate Cancer

Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine, shared a post on X about a paper by Dongyin He et al. published in PNAS:

“New player in ARPI-resistant prostate cancer!

HEAL-116, a next-gen 3βHSD1 inhibitor, shows potent tumor suppression, synergy with abiraterone/enzalutamide, and high oral bioavailability.

Structure-guided. Clinically promising.”

Title: Fine structural design of 3βHSD1 inhibitors for prostate cancer therapy

Authors: Dongyin He, Luyao Zhang, Leiye Yu, Yuhang Zhang, Jingjing Chen, Leibo Wang, Haoran Hu, Hongyu Liu, Hong Zheng, Jixin Xia, Jiahui Chen, Chenhui Li, Xin Li, Huiru Tang, Jia Liu, Ruobing Ren, Youhong Hu, Zhenfei Li.

You can read the Full Article in PNAS.

Yüksel Ürün: New Player in ARPI-Resistant Prostate Cancer

More posts featuring Yüksel Ürün.

ARPI-resistant prostate cancer cancer Chenhui Li Dongyin He Haoran Hu Hong Zheng Hongyu Liu Huiru Tang Jia Liu Jiahui Chen Jingjing Chen Jixin Xia Leibo Wang Leiye Yu Luyao Zhang OncoDaily Oncology prostate cancer Ruobing Ren Xin Li Youhong Hu Yuhang Zhang Yüksel Ürün Zhenfei Li

Garo Armen Shares a Personal Story Driving Agenus' Mission in Cancer Care

Dr. Oliver Bogler, PhD: Leaving the National Cancer Institute

Oncologist Near Me – Rana McKay: A Rising Force in Genitourinary Cancer Research and Care

Sibylle Loibl: Final survival Results from the PENELOPE-B trial published in Annals of Oncology

Yvonne Awards 2025: Honoring Global Oncology Leaders at ASCO’s Most Inspiring Night